+ Larger Font | - Smaller Font
Share


Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Scientific News Tavanta Therapeutics Announces New Preclinical Data For Its Cystic Fibrosis Candidate Tavt 135 At Two Prominent Scientific Conferences is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.
Search RobinsPost News & Noticias


Scientific News Tavanta Therapeutics Announces New Preclinical Data For Its Cystic Fibrosis Candidate Tavt 135 At Two Prominent Scientific Conferences | RobinsPost News & Noticias

Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control


The Company also presented preclinical data validating a novel pharmacodynamic biomarker assay for monitoring on-target engagement and activity of its clinical-stage EC candidate ... Ph.D., Chief ... Read More

Tenaya Therapeutics Announces Publication of TN-401 Gene Therapy Preclinical Data in Nature Communications Medicine


March 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics ... today announced the publication of its preclinical research related to its gene therapy candidate, TN-401, in the current issue of ... Read More

Affini-T Therapeutics Presents Preclinical Data from its Oncogenic Driver Programs Targeting KRAS G12D and p53 R175H at the American Association for Cancer Research (AACR ...


In addition, the team is presenting two trial-in-progress ... Ph.D., Chief Scientific Officer, Affini-T Therapeutics. “We are also proud to present preclinical data from our cell therapy ... Read More

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting


April 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics ... that new preclinical data showing the structural and molecular mechanisms underlying anti-tumor activity of its novel STAT3 degrader ... Read More

Immunitas Therapeutics Presents Preclinical Data Supporting Combination of IMT-009 with Anti-PD1 Immunotherapy at the AACR 2024 Annual Meeting


This need has fueled our work to develop IMT-009 as a differentiated cancer treatment option for patients," said Annalisa D'Andrea, Chief Scientific ... its ligand, CLEC2D. Preclinical data ... Read More

Volastra Therapeutics Announces New and Expanded Partnerships with AI and Precision-Medicine Leaders to Broaden Potential of KIF18A Inhibitors Across Cancer


NEW YORK--(BUSINESS WIRE)--Volastra Therapeutics, a clinical-stage biotechnology company, today announced partnerships with Microsoft, Function Oncology and Tailor Bio with the goal of broadening ... Read More

Cystic Fibrosis


Enterprise Therapeutics ... of the cystic fibrosis medicines Kaftrio (ivacaftor, tezacaftor and elexacaftor) and Kalydeco (ivacaftor) for children aged two to five years old. A new study by ... Read More

Stoke Therapeutics Stock Rockets On Phase 1/2a Data: Here's Why


The company reports quarterly losses of 60 cents per share which beat the analyst consensus estimate of 63 cents per share by 4.76%. Stoke Therapeutics announces new data from two open-label Phase ... Read More

ALGS Aligos Therapeutics, Inc.


focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a ... Read More

CLDX Celldex Therapeutics, Inc.


Celldex Therapeutics ... its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey. Read More

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting


New preclinical data on novel E3 pairing and structural mechanisms ... implied and express statements by Kymera Therapeutics regarding its: strategy, business plans and objectives for its clinical ... Read More

Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting


New preclinical data on novel E3 pairing and structural ... implied and express statements by Kymera Therapeutics regarding its: strategy, business plans and objectives for its clinical programs ... Read More


Blow Us A Whistle


Comments (Whistles) Designed By Disqus